Top Stories

Parkinson’s Disease Market Insight, Industry Analysis Report With Teva Pharmaceutical, GlaxoSmithKline, Adamas Pharmaceuticals, Immutep, Novartis, AbbVie, Acorda Therapeutics, Amneal Pharmaceuticals, Imugene Limited

Global parkinson’s disease market is rising gradually to an estimated value of USD 9.7 Billion by 2026 registering a healthy CAGR of 12.2% in the forecast period of 2019-2026. This significant rise in market value can increase research development initiatives to launching novel therapies.

To Get The Free Sample Of Report, Click On: https://databridgemarketresearch.com/request-a-sample/?dbmr=global-parkinsons-disease-market

Parkinson’s disease is chronic and progressive neurodegenerative disorders that affects dopamine producing neurons in central nervous system. Parkinson’s disease tends to develops in brain over many years. The patient with Parkinson’s disease experience tremor, slow movement, rigid muscle, impaired posture and balance, loss of automatic movements, slurry speech and others.

According to the Clinical Practice Research Data link summary report 2018, it is identified that there were 145,519 prevalence cases of patient with age 20 and above with Parkinson’s disease in UK seen in the year 2018. The estimation incidence cases were 18,461 in patient aged above 45 or over. This significant rise in patient number acts as a driver for the growth of Parkinson’s disease Market.

Market Drivers

  • Increase in prevalence rate of parkinson’s disease worldwide
  • Exposure to certain toxin or change in environment may increase the parkinson’s disease
  • The launch of new products and research collaboration are the prime strategies to reinforce the market position
  • Growing in aging population as it affect most commonly in geriatric population
  • Increase in the rate of R&D initiatives is driving parkinson’s disease drug therapeutics market

Market Restraints

  • High cost involved in the treatment
  • Patent expiry from many companies and introduction of generic drugs is expected to restrain the growth if the market
  • Lack of awareness among the patient and physician about parkinson’s disease treatment

Access the TOC of the Parkinson’s Disease Market report: https://databridgemarketresearch.com/toc/?dbmr=global-parkinsons-disease-market

Key Developments in the Market:

  • In February 2018, Osmotica Pharmaceuticals plc received FDA approval for Osmolex ER (amantadine hydrochloride) which is an extended release tablet indicated for the treatment of parkinson’s disease and drug-induced extrapyramidal reactions in adult patients
  • In August 2017, Adamas Pharmaceuticals, Inc. received FDA approval Gocovri (amantadine) extended release tablet for the treatment of dyskinesia in patients with parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications

 

Segmentation: Global Parkinson’s Disease Market

By Type

  • Drug-induced parkinsonism
  • Vascular parkinsonism
  • Normal pressure hydrocephalus (NSA)
  • Corticobasal degeneration (CBD)
  • Progressive supranuclear palsy (PSP)
  • Multiple system atrophy (MSA)
  • Idiopathic Parkinson’s
  • Others

By Mechanism of Cation type

  • Dopamine agonists
  • Monoamine oxidase B (MAO-B) inhibitors
  • Catechol-O-methyltransferase (COMT) inhibitors
  • Adenosine A2 receptor antagonist

By Drug Type

  • Amantadine
  • Safinamide
  • Brivaracetam
  • Pimavanserin
  • Carbidopa and levodopa
  • Rivastigmine tartrate
  • Rotigotine
  • Ferampanel
  • Apomorphine hydrochloride
  • Pramipexole
  • Others

By Therapy

  • Medication
  • Deep brain stimulation
  • Others

By Route of administration

  • Oral
  • Parenteral
  • Sublingual
  • Others

By End Users

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

By Geography

  • North America
    • S.
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Turkey
    • Belgium
    • Netherlands
    • Switzerland
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • South Korea
    • India
    • Australia
    • Singapore
    • Thailand
    • Malaysia
    • Indonesia
    • Philippines
    • Rest of Asia-Pacific
  • Middle East & Africa
    • South Africa
    • Egypt
    • Saudi Arabia
    • United Arab Emirates
    • Israel
    • Rest of Middle East & Africa

Competitive Analysis: Global Parkinson’s Disease Market

Global parkinson’s disease market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of parkinson’s disease market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Want Full Report? Make Inquiries For Your Custom Requirements: https://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-parkinsons-disease-market

About Us

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. Get Customization and Discount on Report by emailing sopan.gedam@databridgemarketresearch.com . We are content with our glorious 99.9 % client satisfying rate.


Contact Us

Data Bridge Market Research
Toll Free: +1-888-387-2818
Mail: sopan.gedam@databridgemarketresearch.com
https://databridgemarketresearch.com

Tags

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *